Evidence map›Paper›PMID 38656242›Full record

ArticleTechnology in cancer research & treatment

Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer.

Sujuan Peng, Hongxiang Huang, Jinhong Chen, Xinjing Ding, Xie Zhu, Yangyang Liu, Li Chen, Zhihui Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sujuan PengDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Hongxiang HuangDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Jinhong ChenDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Xinjing DingDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Xie ZhuDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Yangyang LiuDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Li ChenDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.
Zhihui LuDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Jiangxi, China.ORCID 0009-0008-2131-4443
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiogenesis InhibitorsCarcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsSARS-CoV-2Severity of Illness IndexAgedFemaleHumansIntensive Care UnitsMaleMiddle AgedRetrospective StudiesRisk FactorsAngiogenesis Inhibitorsanti-angiogenic drugscoronavirus disease 2019COVID-19 severitynon-small cell lung cancerrisk factors

Identifiers

PMID38656242
PMCPMC11044805
OpenAlexW4395071785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.